NCT07824323RecruitingPhase 4
Early Triple Lipid-Lowering Therapy With Bempedoic Acid After Acute Coronary Syndrome
EARLY-BIRD ACS Trial: Early Aggressive Lipid-Lowering Regimen With Bempedoic Acid Initiated for Reducing Dyslipidemia in Patients With Acute Coronary Syndrome
Source: ClinicalTrials.gov · Last updated 17 Sept 2026
Brief summary (registry, in English)
This randomized clinical trial will evaluate whether starting bempedoic acid in addition to high-intensity statin therapy and ezetimibe within 72 hours after percutaneous coronary intervention improves low-density lipoprotein cholesterol (LDL-C) control in adults with acute coronary syndrome. Participants will receive either triple therapy with a high-intensity statin, ezetimibe, and bempedoic acid or standard dual therapy with a high-intensity statin and ezetimibe for 12 weeks. The primary outcome is the proportion of participants with LDL-C below 55 mg/dL at Week 12. Changes in lipid and inflammatory markers, medication adherence, and treatment-emergent adverse events will also be assessed.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 4
- Study type
- Interventional
- Enrollment
- 400 (estimated)
- First submitted
- 11 Sept 2026
- Start date
- Aug 2026
- Primary completion date
- Mar 2028
- Lead sponsor
- Taipei Medical University Hospital
- Diseases
- Coronary artery disease
- NCT number
- NCT07824323
What you commit to
- Study type: Interventional · Phase 4
- Planned participants: 400
- From Aug 2026 to the primary completion date, Mar 2028
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Current use of a PCSK9 inhibitor or fibrate at baseline.
- Known gallbladder disease, including cholelithiasis or previous cholecystitis.
Other illness
- History of symptomatic hyperuricemia or gout.
- Active systemic infection or acute inflammatory disease that could interfere with hs-CRP interpretation.
Lab values
- Severe hepatic impairment, defined as ALT or AST greater than 3 times the upper limit of normal at screening.
- Triglycerides of at least 400 mg/dL at screening.
Other
- Known intolerance or contraindication to statins, ezetimibe, or bempedoic acid.
- Estimated glomerular filtration rate below 30 mL/min/1.73 m2 or dialysis.
- Current participation in another interventional clinical trial.
- Pregnancy, breastfeeding, or planned pregnancy during the study period.
Who the study is looking for
- Age 18 years or older.
- Confirmed acute coronary syndrome, including ST-elevation myocardial infarction, non-ST-elevation myocardial infarction, or unstable angina.
- Percutaneous coronary intervention within the preceding 72 hours.
- Baseline LDL-C of at least 70 mg/dL.
- Able and willing to provide written informed consent.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Taipei Medical University Hospital Coordinator of this site? Confirm its status | Taipei | Taiwan | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.